CN103768032A - Baohuoside I tablet and preparation method thereof - Google Patents
Baohuoside I tablet and preparation method thereof Download PDFInfo
- Publication number
- CN103768032A CN103768032A CN201410020757.7A CN201410020757A CN103768032A CN 103768032 A CN103768032 A CN 103768032A CN 201410020757 A CN201410020757 A CN 201410020757A CN 103768032 A CN103768032 A CN 103768032A
- Authority
- CN
- China
- Prior art keywords
- baohuoside
- tablet
- disintegrating agent
- granulate
- gained
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Abstract
The invention discloses a baohuoside I tablet, which is prepared from the following raw materials in parts by weight: 6-30 parts of baohuoside I, 55-86 parts of diluents, 1.5-2.5 parts of adhesives, 1.5-7 parts of disintegrants, 0.5-5 parts of lubricants, and 0.1-6 parts of surfactants. The method for preparing the baohuoside I tablet comprises the following steps: weighing, mixing, crushing, pelletizing, drying, granulating, blending and tabletting. The baohuoside I tablet has the beneficial effects that the baohuoside I tablet disclosed by the invention has the advantages of being easy to disintegrate in water, high in dissolution rate, even to disperse and convenient to take, and the preparation method has the characteristics of being simple in process, convenient to operate, and low in production cost.
Description
Technical field
The present invention relates to a kind of baohuoside Ⅰ tablet and preparation method thereof, belong to medical technical field.
Background technology
Herba Epimedii, is a kind of traditional traditional tonic medicine, has the multiple efficacies such as kidney-replenishing, bone and muscle strengthening, wind-damp dispelling, is used for the treatment of impotence and seminal emission, and muscles and bones flaccidity is soft, rheumatic arthralgia, numbness contracture, climacteric hypertension.Baohuoside Ⅰ (Baohuoside I), have another name called icariside II (I carisid II), chemical name: 3,5,7-trihydroxy-4 '-methoxyl group-8-isoamylene radical chromocor-3-0-ɑ-L-pyrans rhamnoside, chemical constitution, as shown in (I), is a kind of polyhydroxy flavonoid monomer component, in Cortex Acanthopancis, pubescence Herba Epimedii, has a small amount of existence.Baohuoside Ⅰ have than icariin more by force, pharmacologically active widely, there is outstanding osteoporosis, improve effect of body immunity, antioxidation, control cardiovascular and cerebrovascular disease; The degenerative disease such as senile dementia are also had to good preventive and therapeutic action.Baohuoside Ⅰ has the effect of obvious growth inhibited and cell death inducing to cancerous cell, it is relevant with the expression of lowering apoptosis suppressor SURFvivin that mechanism of action is considered to.Think in the industry for the barrier antitumor therapy of target survivin, will open up new way for the treatment of tumor.In addition, baohuoside Ⅰ also has the pharmacological action identical with icariin part equally, is the raw material of the multiple new drug of exploitation and functional food, has a extensive future.Therefore, the research work of baohuoside Ⅰ is at home and abroad all quite paid attention to.
But because baohuoside Ⅰ oral absorption is poor, bioavailability is low, limit the performance of baohuoside Ⅰ drug effect.Chinese patent CN102309469A has announced Foradil Aerolizer formoterol fumarate of a kind of baohuoside Ⅰ and its production and use.It is take baohuoside Ⅰ as active substance, the pharmaceutical composition being prepared from pharmaceutically acceptable adjuvant.Although Foradil Aerolizer formoterol fumarate does not use propellant and solvent, rely on air-flow to make drug powder atomization, and then make drug powder be delivered to pulmonary, it is a kind of Novel Drug Delivery Systems, improved the effect of baohuoside Ⅰ treatment lung tumors compared with oral administration, but the dosage form manufacturing technique complexity of Foradil Aerolizer formoterol fumarate, and production cost is high, and patient's medication poor compliance, is not suitable for large-scale production.
Oral administration is current modal administering mode, because of its production technology simple, patient is easy to carry and use and quite liked, and baohuoside Ⅰ oral absorption is poor, bioavailability is low, therefore, prepare that dissolution is high, good absorbing, the baohuoside Ⅰ tablet that bioavailability is high becomes the research emphasis of field of medicaments.
Summary of the invention
The object of the invention is to overcome the shortcoming of prior art, a kind of baohuoside Ⅰ tablet is provided, this tablet has advantages of that in water easy disintegrating, dissolution are high, is uniformly dispersed, taking convenience; Another object of the present invention is to provide the preparation method of baohuoside Ⅰ tablet, the method has the characteristic that technique is simple, easy to operate, production cost is low.
Object of the present invention is achieved through the following technical solutions: a kind of baohuoside Ⅰ tablet, and it is made up of the raw material of following weight parts:
Baohuoside Ⅰ 6～30, diluent 55～86,
Adhesive 1.5～2.5, disintegrating agent 1.5～7,
Lubricant 0.5～5, surfactant 0.1～6.
As optimization, it is made up of the raw material of following weight parts:
Baohuoside Ⅰ 14, diluent 74,
Adhesive 1.7, disintegrating agent 4.3,
Lubricant 1.3, surfactant 2.9.
Described diluent is lactose monohydrate, vertical compression lactose, spray one or more in dry lactose, glucose, mannitol, sorbitol, microcrystalline Cellulose PH101, microcrystalline Cellulose PH102, sucrose, corn starch.
Described adhesive is one or more in starch slurry, pregelatinized Starch, PVP K30,30 POVIDONE K 30 BP/USP 90, hydroxypropyl cellulose, sodium carboxymethyl cellulose.
Described disintegrating agent is one or more in polyvinylpolypyrrolidone, cross-linking sodium carboxymethyl cellulose, crosslinked carboxymethyl fecula sodium, low-substituted hydroxypropyl cellulose.
Described lubricant is one or more in stearic acid, magnesium stearate, micropowder silica gel, Pulvis Talci, sodium stearyl fumarate.
Described surfactant is one or more in micronization PLURONICS F87, micronization poloxamer188, sodium lauryl sulphate, polyoxyl 40 hydrogenated castor oil, Solutol HS15, sorbitan monooleate polyoxyethylene ether.
The preparation method of above-mentioned baohuoside Ⅰ tablet, it comprises the following steps:
S1. weigh: take each raw material by above-mentioned formula, and by two parts of A, the B of the weight such as load weighted disintegrating agent is divided into, for subsequent use;
S2. mix: by load weighted baohuoside Ⅰ, diluent, A part disintegrating agent, surfactant mix homogeneously;
S3. pulverize: the part material of above-mentioned mix homogeneously is placed in to pulverizer and pulverizes, be ground into the powder that particle diameter is 140～160 μ m;
S4. granulate: adhesive is dissolved in 90～98% alcoholic solution, and adds the powder of step S3 gained, then cross 20～30 eye mesh screens and granulate;
S5. dry: use fluid bed to be dried, baking temperature is set as 45～55 ℃, moisture Control, 3～8%, is dried 45～55min;
S6. granulate: the dried granule of step S5 gained is crossed to 18～25 eye mesh screens and carry out granulate;
S7. always mixed: step S6 gained granule to be placed in to mixer, then to add B part disintegrating agent, lubricant, mix 15～25min;
S8. tabletting: step S7 gained is always mixed to thing and carry out tabletting, make baohuoside Ⅰ tablet.
The present invention has the following advantages:
1. dissolubility and the dissolution in vitro of baohuoside Ⅰ in water is very low, fills a prescription and preparation method has significantly increased the dissolution of baohuoside Ⅰ tablet by the present invention, has strengthened the bioavailability of medicine, and has had easy disintegrating, finely dispersed advantage in water; The present invention's formula is easy to film-making, and the slice, thin piece hardness of utilizing the inventive method to extrude is moderate, unilateral smooth.
2. in the present invention's formula, added surfactant, the baohuoside Ⅰ of slightly solubility in preparation method and a large amount of hydrophilicity condiments and a small amount of surfactant are carried out to co-grinding, strengthened the hydrophilic of baohuoside Ⅰ, make baohuoside Ⅰ easily wetted, therefore, significantly increased dissolution.
3. be hydrolyzed into baohuoside Ⅰ and be absorbed because icariin only enters in body small part, bioavailability is lower, and the present invention directly uses baohuoside Ⅰ as principal agent, reduces the inventory of raw material, has also increased the bioavailability of principal agent simultaneously.
4. preparation technology of the present invention is wet granule compression tablet method, to equipment require lowly, significantly reduced production cost, be suitable for the large-scale production of baohuoside Ⅰ tablet.
Accompanying drawing explanation
Fig. 1 is baohuoside Ⅰ Dissolution of Tablet curve chart prepared by prescription 1-3;
Fig. 2 is the average dissolution curve chart of baohuoside Ⅰ tablet prepared by prescription 4-11.
The specific embodiment
Below in conjunction with embodiment, the present invention will be further described, and protection scope of the present invention is not limited to the following stated.
Embodiment 1: a kind of baohuoside Ⅰ tablet, it is made up of the raw material of following weight parts: baohuoside Ⅰ 6, diluent 55, adhesive 1.5, disintegrating agent 1.5, lubricant 0.5, surfactant 0.1;
Described diluent is lactose monohydrate, vertical compression lactose, microcrystalline Cellulose PH101, microcrystalline Cellulose PH102, and weight ratio is 1:2:2:1; Described adhesive is PVP K30, sodium carboxymethyl cellulose, and weight ratio is 1:1; Described disintegrating agent is polyvinylpolypyrrolidone, cross-linking sodium carboxymethyl cellulose, and weight ratio is 1:2; Described lubricant is stearic acid, Pulvis Talci, sodium stearyl fumarate, and weight ratio is 3:1:1; Described surfactant is micronization PLURONICS F87, micronization poloxamer188, and weight ratio is 2:3.
The preparation method of above-mentioned baohuoside Ⅰ tablet, it comprises the following steps:
S1. weigh: take each raw material by above-mentioned formula, and by two parts of A, the B of the weight such as load weighted disintegrating agent is divided into, for subsequent use;
S2. mix: by load weighted baohuoside Ⅰ, diluent, A part disintegrating agent, surfactant mix homogeneously;
S3. pulverize: the part material of above-mentioned mix homogeneously is placed in to pulverizer and pulverizes, be ground into the powder that particle diameter is 140 μ m;
S4. granulate: adhesive is dissolved in 90～98% alcoholic solution, and adds the powder of step S3 gained, then cross 20 eye mesh screens and granulate;
S5. dry: use fluid bed to be dried, baking temperature is set as 45 ℃, moisture Control, 3%, is dried 45min;
S6. granulate: the dried granule of step S5 gained is crossed to 18 eye mesh screens and carry out granulate;
S7. always mixed: step S6 gained granule to be placed in to mixer, then to add B part disintegrating agent, lubricant, mix 15min;
S8. tabletting: step S7 gained is always mixed to thing and carry out tabletting, make baohuoside Ⅰ tablet.
Embodiment 2: a kind of baohuoside Ⅰ tablet, it is made up of the raw material of following weight parts: baohuoside Ⅰ 30, diluent 86, adhesive 2.5, disintegrating agent 7, lubricant 5, surfactant 6;
Described diluent is glucose, mannitol, sorbitol, sucrose, corn starch, and weight ratio is 1:1:5:3:3; Described adhesive is 30 POVIDONE K 30 BP/USP 90; Described disintegrating agent is polyvinylpolypyrrolidone, low-substituted hydroxypropyl cellulose, and weight ratio is 5:3; Described lubricant is micropowder silica gel, Pulvis Talci, and weight ratio is 2:1; Described surfactant is sodium lauryl sulphate.
The preparation method of above-mentioned baohuoside Ⅰ tablet, it comprises the following steps:
S1. weigh: take each raw material by above-mentioned formula, and by two parts of A, the B of the weight such as load weighted disintegrating agent is divided into, for subsequent use;
S2. mix: by load weighted baohuoside Ⅰ, diluent, A part disintegrating agent, surfactant mix homogeneously;
S3. pulverize: the part material of above-mentioned mix homogeneously is placed in to pulverizer and pulverizes, be ground into the powder that particle diameter is 160 μ m;
S4. granulate: adhesive is dissolved in 90～98% alcoholic solution, and adds the powder of step S3 gained, then cross 30 eye mesh screens and granulate;
S5. dry: use fluid bed to be dried, baking temperature is set as 55 ℃, moisture Control, 8%, is dried 55min;
S6. granulate: the dried granule of step S5 gained is crossed to 25 eye mesh screens and carry out granulate;
S7. always mixed: step S6 gained granule to be placed in to mixer, then to add B part disintegrating agent, lubricant, mix 25min;
S8. tabletting: step S7 gained is always mixed to thing and carry out tabletting, make baohuoside Ⅰ tablet.
Embodiment 3: a kind of baohuoside Ⅰ tablet, it is made up of the raw material of following weight parts: baohuoside Ⅰ 14, diluent 74, adhesive 1.7, disintegrating agent 4.3, lubricant 1.3, surfactant 2.9;
Described diluent is sorbitol, starch slurry, and weight ratio is 3:2; Described adhesive is PVP K30,30 POVIDONE K 30 BP/USP 90, and weight ratio is 4:3; Described disintegrating agent is cross-linking sodium carboxymethyl cellulose, crosslinked carboxymethyl fecula sodium, and weight ratio is 1.5:1; Described lubricant is stearic acid; Described surfactant is polyoxyl 40 hydrogenated castor oil.
The preparation method of above-mentioned baohuoside Ⅰ tablet, it comprises the following steps:
S1. weigh: take each raw material by above-mentioned formula, and by two parts of A, the B of the weight such as load weighted disintegrating agent is divided into, for subsequent use;
S2. mix: by load weighted baohuoside Ⅰ, diluent, A part disintegrating agent, surfactant mix homogeneously;
S3. pulverize: the part material of above-mentioned mix homogeneously is placed in to pulverizer and pulverizes, be ground into the powder that particle diameter is 150 μ m;
S4. granulate: adhesive is dissolved in 90～98% alcoholic solution, and adds the powder of step S3 gained, then cross 22 eye mesh screens and granulate;
S5. dry: use fluid bed to be dried, baking temperature is set as 50 ℃, moisture Control, 5%, is dried 48min;
S6. granulate: the dried granule of step S5 gained is crossed to 20 eye mesh screens and carry out granulate;
S7. always mixed: step S6 gained granule to be placed in to mixer, then to add B part disintegrating agent, lubricant, mix 18min;
S8. tabletting: step S7 gained is always mixed to thing and carry out tabletting, make baohuoside Ⅰ tablet.
Embodiment 4: a kind of baohuoside Ⅰ tablet, it is made up of the raw material of following weight parts: baohuoside Ⅰ 30, diluent 60, adhesive 2.3, disintegrating agent 4.8, lubricant 3.6, surfactant 4;
Described diluent is the dry lactose of spray, glucose, mannitol, sorbitol, and weight ratio is 5:1:1:3; Described adhesive is PVP K30,30 POVIDONE K 30 BP/USP 90, and weight ratio is 2:5; Described disintegrating agent is cross-linking sodium carboxymethyl cellulose, crosslinked carboxymethyl fecula sodium, low-substituted hydroxypropyl cellulose, and weight ratio is 9:3:2; Described lubricant is micropowder silica gel, Pulvis Talci, and weight ratio is 2:3; Described surfactant is polyoxyl 40 hydrogenated castor oil, Solutol HS15, sorbitan monooleate polyoxyethylene ether, and weight ratio is 1.8:2:1.
The preparation method of above-mentioned baohuoside Ⅰ tablet, it comprises the following steps:
S1. weigh: take each raw material by above-mentioned formula, and by two parts of A, the B of the weight such as load weighted disintegrating agent is divided into, for subsequent use;
S2. mix: by load weighted baohuoside Ⅰ, diluent, A part disintegrating agent, surfactant mix homogeneously;
S3. pulverize: the part material of above-mentioned mix homogeneously is placed in to pulverizer and pulverizes, be ground into the powder that particle diameter is 155 μ m;
S4. granulate: adhesive is dissolved in 90～98% alcoholic solution, and adds the powder of step S3 gained, then cross 25 eye mesh screens and granulate;
S5. dry: use fluid bed to be dried, baking temperature is set as 50 ℃, moisture Control, 7%, is dried 50min;
S6. granulate: the dried granule of step S5 gained is crossed to 22 eye mesh screens and carry out granulate;
S7. always mixed: step S6 gained granule to be placed in to mixer, then to add B part disintegrating agent, lubricant, mix 20min;
S8. tabletting: step S7 gained is always mixed to thing and carry out tabletting, make baohuoside Ⅰ tablet.
Embodiment 5: a kind of baohuoside Ⅰ tablet, it is made up of the raw material of following weight parts: baohuoside Ⅰ 25, diluent 60, adhesive 2.5, disintegrating agent 4, lubricant 3.2, surfactant 2;
Described diluent is the dry lactose of spray; Described adhesive is PVP K30, sodium carboxymethyl cellulose, and weight ratio is 3:4; Described disintegrating agent is polyvinylpolypyrrolidone, cross-linking sodium carboxymethyl cellulose, crosslinked carboxymethyl fecula sodium, low-substituted hydroxypropyl cellulose, and weight ratio is 2:5:3:3; Described lubricant is magnesium stearate, micropowder silica gel, and weight ratio is 2.5:1; Described surfactant is micronization PLURONICS F87, sodium lauryl sulphate, Solutol HS15, and weight ratio is 3:2:2.
The preparation method of above-mentioned baohuoside Ⅰ tablet, it comprises the following steps:
S1. weigh: take each raw material by above-mentioned formula, and by two parts of A, the B of the weight such as load weighted disintegrating agent is divided into, for subsequent use;
S2. mix: by load weighted baohuoside Ⅰ, diluent, A part disintegrating agent, surfactant mix homogeneously;
S3. pulverize: the part material of above-mentioned mix homogeneously is placed in to pulverizer and pulverizes, be ground into the powder that particle diameter is 155 μ m;
S4. granulate: adhesive is dissolved in 90～98% alcoholic solution, and adds the powder of step S3 gained, then cross 28 eye mesh screens and granulate;
S5. dry: use fluid bed to be dried, baking temperature is set as 52 ℃, moisture Control, 7%, is dried 52min;
S6. granulate: the dried granule of step S5 gained is crossed to 23 eye mesh screens and carry out granulate;
S7. always mixed: step S6 gained granule to be placed in to mixer, then to add B part disintegrating agent, lubricant, mix 22min;
S8. tabletting: step S7 gained is always mixed to thing and carry out tabletting, make baohuoside Ⅰ tablet.
Embodiment 6: dissolution experiment
1. prepare baohuoside Ⅰ tablet: by formula preparation baohuoside Ⅰ tablet in table 1, table 2.
Table 1: the formula (A) of baohuoside Ⅰ tablet
Table 2: the formula (B) of baohuoside Ⅰ tablet
The method of preparing baohuoside Ⅰ tablet according to above-mentioned prescription 1-11, it comprises the following steps:
S1. weigh: take each raw material by above-mentioned formula, and by two parts of A, the B of the weight such as load weighted disintegrating agent is divided into, for subsequent use;
S2. mix: by load weighted baohuoside Ⅰ, diluent, A part disintegrating agent, surfactant mix homogeneously;
S3. pulverize: the part material of above-mentioned mix homogeneously is placed in to pulverizer and pulverizes, be ground into the powder that particle diameter is 140 μ m;
S4. granulate: adhesive is dissolved in 90～98% alcoholic solution, and adds the powder of step S3 gained, then cross 30 eye mesh screens and granulate;
S5. dry: use fluid bed to be dried, baking temperature is set as 55 ℃, moisture Control, 6%, is dried 55min;
S6. granulate: the dried granule of step S5 gained is crossed to 20 eye mesh screens and carry out granulate;
S7. always mixed: step S6 gained granule to be placed in to mixer, then to add B part disintegrating agent, lubricant, mix 20min;
S8. tabletting: step S7 gained is always mixed to thing and carry out tabletting, make baohuoside Ⅰ tablet.
2. experimental technique:
Get the baohuoside Ⅰ tablet of above-mentioned preparation, according to dissolution method (two appendix XC the second methods of Chinese Pharmacopoeia version in 2010), take PH4.5 medium (add respectively 1% sodium lauryl sulphate) 900ml as dissolution medium, 50 revs/min of rotating speeds, operation in accordance with the law, in 5min, 10min, 15min, 20min, 30min, 45min, 60min minute sampling, filters respectively, get filtrate as need testing solution, supply with blank medium simultaneously; Separately get the about 25mg of baohuoside Ⅰ reference substance, to 50ml, separately get 1ml solution by methanol constant volume, then be settled in 10ml volumetric flask and do reference substance solution with dissolution medium.Get above-mentioned two kinds of solution, measure its content according to high performance liquid chromatography (two appendix VD of Chinese Pharmacopoeia version in 2010), and calculate the stripping quantity of every.Limit is 85% of labelled amount, should conform with the regulations.
Chromatographic condition
Chromatographic column: C18 reversed-phase bonded silica chromatographic column
Mobile phase: methanol-water: 80-20
Detect wavelength: 270nm
3. experimental result: as shown in Figure 1 and Figure 2, the dissolution curve of the baohuoside Ⅰ tablet of preparing for the inventive method, experimental result data is as shown in table 3, table 4.
Table 3: baohuoside Ⅰ Dissolution of Tablet experimental data (A)
From Fig. 1, table 3: prescription 1,2, the 3 baohuoside Ⅰ tablets that make are respectively 87.88%, 86.03%, 88.78% at the dissolution of 30min, are respectively 90.79%, 90.35%, 93.17% at the dissolution of 60min.Result shows: prescription can be dispersed in dissolution medium after 1 disintegrate, and prescription 2 disintegrates and stripping behavior are all better, and the disintegrate behavior of prescription 31,2 disintegrates of writing out a prescription are slightly fast.
Table 4: baohuoside Ⅰ Dissolution of Tablet experimental data (B)
From Fig. 2, table 4: the baohuoside Ⅰ tablet that prescription 4-11 makes is 87.84% in the average dissolution of 30min, the average dissolution of 60min is 92.73%, result shows: the baohuoside Ⅰ that 8 prescriptions make all can reach the limitation at 30min dissolution (labelled amount 85%), and final dissolution all can reach more than 90%, illustrate that the baohuoside Ⅰ tablet that the present invention makes has high-dissolution, is uniformly dispersed, the characteristic of easy disintegrating not.
Claims (8)
1. a baohuoside Ⅰ tablet, is characterized in that, it is made up of the raw material of following weight parts:
Baohuoside Ⅰ 6～30, diluent 55～86,
Adhesive 1.5～2.5, disintegrating agent 1.5～7,
Lubricant 0.5～5, surfactant 0.1～6.
2. a kind of baohuoside Ⅰ tablet according to claim 1, is characterized in that, it is made up of the raw material of following weight parts:
Baohuoside Ⅰ 14, diluent 74,
Adhesive 1.7, disintegrating agent 4.3,
Lubricant 1.3, surfactant 2.9.
3. a kind of baohuoside Ⅰ tablet according to claim 1 and 2, it is characterized in that, described diluent is lactose monohydrate, vertical compression lactose, spray one or more in dry lactose, glucose, mannitol, sorbitol, microcrystalline Cellulose PH101, microcrystalline Cellulose PH102, sucrose, corn starch.
4. a kind of baohuoside Ⅰ tablet according to claim 1 and 2, is characterized in that, described adhesive is one or more in starch slurry, pregelatinized Starch, PVP K30,30 POVIDONE K 30 BP/USP 90, hydroxypropyl cellulose, sodium carboxymethyl cellulose.
5. a kind of baohuoside Ⅰ tablet according to claim 1 and 2, is characterized in that, described disintegrating agent is one or more in polyvinylpolypyrrolidone, cross-linking sodium carboxymethyl cellulose, crosslinked carboxymethyl fecula sodium, low-substituted hydroxypropyl cellulose.
6. a kind of baohuoside Ⅰ tablet according to claim 1 and 2, is characterized in that, described lubricant is one or more in stearic acid, magnesium stearate, micropowder silica gel, Pulvis Talci, sodium stearyl fumarate.
7. a kind of baohuoside Ⅰ tablet according to claim 1 and 2, it is characterized in that, described surfactant is one or more in micronization PLURONICS F87, micronization poloxamer188, sodium lauryl sulphate, polyoxyl 40 hydrogenated castor oil, Solutol HS15, sorbitan monooleate polyoxyethylene ether.
8. the preparation method of a kind of baohuoside Ⅰ tablet according to claim 1 and 2, is characterized in that, it comprises the following steps:
S1. weigh: take each raw material by above-mentioned formula, and by two parts of A, the B of the weight such as load weighted disintegrating agent is divided into, for subsequent use;
S2. mix: by load weighted baohuoside Ⅰ, diluent, A part disintegrating agent, surfactant mix homogeneously;
S3. pulverize: the part material of above-mentioned mix homogeneously is placed in to pulverizer and pulverizes, be ground into the powder that particle diameter is 140～160 μ m;
S4. granulate: adhesive is dissolved in 90～98% alcoholic solution, and adds the powder of step S3 gained, then cross 20～30 eye mesh screens and granulate;
S5. dry: use fluid bed to be dried, baking temperature is set as 45～55 ℃, moisture Control, 3～8%, is dried 45～55min;
S6. granulate: the dried granule of step S5 gained is crossed to 18～25 eye mesh screens and carry out granulate;
S7. always mixed: step S6 gained granule to be placed in to mixer, then to add B part disintegrating agent, lubricant, mix 15～25min;
S8. tabletting: step S7 gained is always mixed to thing and carry out tabletting, make baohuoside Ⅰ tablet.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410020757.7A CN103768032A (en) | 2014-01-16 | 2014-01-16 | Baohuoside I tablet and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410020757.7A CN103768032A (en) | 2014-01-16 | 2014-01-16 | Baohuoside I tablet and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN103768032A true CN103768032A (en) | 2014-05-07 |
Family
ID=50561096
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410020757.7A Pending CN103768032A (en) | 2014-01-16 | 2014-01-16 | Baohuoside I tablet and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103768032A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104173361A (en) * | 2014-06-10 | 2014-12-03 | 遵义医学院 | Application of baohuoside I in preparation of medicines for preventing and treating alzheimer disease |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101516325B (en) * | 2006-09-19 | 2012-03-21 | 株式会社太平洋 | Method for preparing icariside II, cosmetic composition containing the same and the use thereof for skin whitening |
-
2014
- 2014-01-16 CN CN201410020757.7A patent/CN103768032A/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101516325B (en) * | 2006-09-19 | 2012-03-21 | 株式会社太平洋 | Method for preparing icariside II, cosmetic composition containing the same and the use thereof for skin whitening |
Non-Patent Citations (1)
| Title |
|---|
| 胡英等: "《生物药物制剂技术》", 30 September 2010, article "生物药物制剂技术", pages: 182 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104173361A (en) * | 2014-06-10 | 2014-12-03 | 遵义医学院 | Application of baohuoside I in preparation of medicines for preventing and treating alzheimer disease |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104721142B (en) | Rivaroxaban solid dispersion and preparation method thereof | |
| CN106794182B (en) | Pharmaceutical composition containing cyclin inhibitor solid dispersion and preparation method thereof | |
| CN102341095A (en) | Process for preparation of pharmaceutical composition comprising ezetimibe | |
| CN103877051B (en) | A kind of preparation method of Ezetimibe sheet | |
| CN102764264A (en) | Celecoxib solid composition with high dissolution, preparation method and application | |
| CN101816637B (en) | Leflunomide tablet preparation and preparation method thereof | |
| CN105496966A (en) | Medicine composition for Jardiance solid dispersion and preparation method thereof | |
| CN106511348A (en) | Huperzine-A framework particles, orally disintegrating tablets and preparation methods thereof | |
| CN103768032A (en) | Baohuoside I tablet and preparation method thereof | |
| CN104906160B (en) | A kind of enteric coated preparations of erigeron breviscapus extract | |
| CN102626410A (en) | Pharmaceutical composition containing roflumilast | |
| CN109125270B (en) | Solid preparation and preparation method thereof | |
| EP1541161B1 (en) | Tablet composition containing chinese orthodox medicine extract and process for producing the same | |
| CN106539769A (en) | A kind of Lurasidone tablet and preparation method thereof | |
| CN107126420A (en) | A kind of high-dissolution fenofibrate and preparation method thereof | |
| CN102204879A (en) | Preparation method of ginkgolide B solid dispersion | |
| CN105982872B (en) | A kind of arctigenin tablet | |
| CN104546775A (en) | Atorvastatin calcium tablet | |
| CN106606489A (en) | Canagliflozin tablets and preparation method thereof | |
| CN110115715A (en) | A kind of composite tablet and preparation method thereof containing Irbesartan | |
| CN111557914A (en) | Pharmaceutical composition containing ereoxib | |
| CN111000807B (en) | A dripping pill containing ginkgolide as effective component and its preparation method | |
| CN104666260A (en) | Ezetimibe tablet | |
| CN104352465A (en) | Prucalopride succinate pharmaceutical composition free of silicon dioxide and preparation method of prucalopride succinate pharmaceutical composition | |
| CN104337783B (en) | A kind of capecitabine tablet and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C53 | Correction of patent of invention or patent application | ||
| CB02 | Change of applicant information |
Address after: 610017 No. 88 South Park Road, Feng Wan Industrial Park, Chengdu hi tech Zone, Sichuan, China Applicant after: SICHUAN HETAI SYNLIGHT BIOTECHNOLOGY CO., LTD. Address before: 610017 No. 88 South Park Road, Feng Wan Industrial Park, Chengdu hi tech Zone, Sichuan, China Applicant before: Sichuan Kelun Xinguang Biological Science and Technology Development Co., Ltd. |
|
| COR | Change of bibliographic data |
Free format text: CORRECT: APPLICANT; FROM: SICHUAN KELUN XINGUANG BIOTECHNOLOGY DEVELOPMENT CO., LTD. TO: SICHUAN HETAI XINGUANG BIOTECHNOLOGY CO., LTD. |
|
| C12 | Rejection of a patent application after its publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20140507 |